studygraphics
#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events
There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. There were no serious adverse events from the maximum dose of 300 mg ianalumab, and it was well tolerated by trial participants. Evidence Rating Level: 1 (Excellent) Study Rundown: Sjögren’s syndrome is an autoimmune disorder which is currently […]
Read More
#VisualAbstract: Induction chemotherapy with concurrent chemoradiotherapy may improve survival in intermediate-risk pediatric patients with nasopharyngeal carcinoma
Click to read this study in the European Journal of Cancer.
Read More
#VisualAbstract: Convalescent Plasma Ineffective at Improving Clinical Outcomes or Mortality in Non-Ventilated Patients With COVID-19
This meta-analysis found that treatment with COVID-19 convalescent plasma (CCP), compared to control group treatment, did not improve clinical outcomes, as measured by the World Health Organization clinical outcome score, or mortality. There was an improvement in the mortality and clinical outcomes for participants treated with CCP who had a baseline WHO score of 4 […]
Read More
#VisualAbstract: Addition of radiotherapy to anti-PD-1 therapy does not improve survival in advanced mucosal melanoma
Click to read this study in the European Journal of Cancer.
Read More